No partner can do it all. While top CROs have global staff and broad therapeutic area expertise, capability gaps exist, particularly in emerging, innovative arenas like gene therapy and cell therapy launches. Also, a large study cutover volume often strains CRO operating models, requiring significant resource drain within a particular skill area – a surefire way to put study timelines at risk!
In exchange for a partnership, biopharma companies should realize tangible benefits in terms of both pricing and delivery. Openly asking for additional benefits or highlighting concerns around pricing, KPIs and experiences is critical, as is tracking of the CRO partners’ ability to address these concerns.
Lastly, it is a substantial mutual benefit for biopharma companies to share their upcoming pipeline and potential award with the CRO so enable optimal study startup and resource planning.
Too often, cost is the only consideration when selecting a CRO partner. Operational excellence, on-time delivery, increased quality, access to innovative tools and budget accuracy are all critical parameters that may be forgotten, leading to a propagation of downstream costs, study delays and lost innovation potential.
How often do study sponsors benchmark pricing across CRO partners, archive study targets vs. outcomes, or most importantly, study true experiences in the partnership? Simple measures to capture this data will empower future studies with defensible, robust data.
Long-term patient monitoring presents a strong opportunity for decentralized trials and remote monitoring, and studies with a heavy APAC-based patient population are growing in frequency. Partnerships must be positioned optimally to take advantage of these trends.
Zeid Barakat brings over 20 years of expertise across the biopharmaceutical value chain as a consultant and entrepreneur. Zeid also serves as an adjunct faculty member in the Tufts CSDD and enjoys playing tennis (former Davis Cup Team of Jordan), chess, and painting.
T: +1 917 363 3438
[email protected]
| Intended Reader Biopharma leaders | Key Takeaways Striking a Balance Between Speed and Safety Global Collaboration for Effective Regulatory Pathways Agile Regulations for Rapidly
| Intended Reader Biopharma leaders | Key Takeaways Striking a Balance Between Speed and Safety Global Collaboration for Effective Regulatory Pathways Agile Regulations for Rapidly
| Intended Reader Biopharma leaders | Key Takeaways Emerging Modalities: Cell and Gene Therapies Engineered Live Biotherapeutics Regulatory Adaptations to Facilitate Innovation Implications for Clinical
| Intended Reader Biopharma leaders | Key Takeaways Harmonization’s impact on RWE and RWD integration Leveraging AI to drive Data Standardization The potential of Harmonization,
| Intended Reader Biopharma leaders | Key Takeaways Transforming Regulatory Processes with AI AI in Drug Discovery and Development Regulatory Challenges and Ethical Considerations The